A comprehensive overview of the relationship between RET gene and tumor occurrence

Lu Zhao; Na Wang; Dou Zhang; Yingjie Jia; Fanming Kong

doi:10.3389/fonc.2023.1090757

A comprehensive overview of the relationship between RET gene and tumor occurrence

Front Oncol. 2023 Feb 14:13:1090757. doi: 10.3389/fonc.2023.1090757. eCollection 2023.

Authors

Lu Zhao^{1

2}, Na Wang^{1

2}, Dou Zhang^{1

2}, Yingjie Jia^{1

2}, Fanming Kong^{1

2}

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

Abstract

RET gene plays significant roles in the nervous system and many other tissues. Rearranged during transfection (RET) mutation is related to cell proliferation, invasion, and migration. Many invasive tumors (e.g., non-small cell lung cancer, thyroid cancer, and breast cancer) were found to have changes in RET. Recently, great efforts have been made against RET. Selpercatinib and pralsetinib, with encouraging efficacy, intracranial activity, and tolerability, were approved by the Food and Drug Administration (FDA) in 2020. The development of acquired resistance is inevitable, and a deeper exploration should be conducted. This article systematically reviewed RET gene and its biology as well as the oncogenic role in multiple cancers. Moreover, we also summarized recent advances in the treatment of RET and the mechanism of drug resistance.

Keywords: RET; breast cancer; lung cancer; targeted therapy; thyroid cancer.

Publication types

Review

Grants and funding

This work is supported by the National Key Research and Development (R&D) plan (2018YFC1707400), the National Natural Science Foundation of China (No. 81403220), and the Tianjin Health and Family Planning-High Level Talent Selection and Training Project.